ERBB2 and breast carcinoma: Furthermore, pharmacologic targeting of HER2 has also gained interest as a potential therapeutic strategy for patients with type II ECs, especially since positive results were obtained for patients with HER2 positive breast cancer as mentioned in Section 5.1.